SMMT

Summit Therapeutics Inc.

September 28, 2026 · after-hours

Rarity

2.25

Peak move

+24.08%

Float cap

$1.7B

Summit Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing patient-friendly therapies for serious unmet medical needs, primarily in oncology. Its lead candidate, ivonescimab, is a bispecific antibody combining PD-1 blockade with anti-VEGF effects, being developed in non-small cell lung cancer and colorectal cancer. The company in-licensed ivonescimab from Akeso for the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa.

• Key eventequity_offeringSep 28

  AstraZeneca agreed to invest $2.0 billion in Summit Therapeutics through about 108,955 convertible preferred shares (1:1,000 conversion) at $18.36 per common share, a 10% premium to the five-day VWAP, giving AstraZeneca roughly 12.0% of Summit's outstanding common stock.

  Webmarketscreener.comWebebs.publicnow.comWebbusinesswire.com
• Key eventmajor_contractSep 28

  Summit Therapeutics entered a clinical collaboration with AstraZeneca to evaluate ivonescimab combined with AstraZeneca's Claudin 18.2-targeting ADC sonesitatug vedotin in gastrointestinal cancers, with AstraZeneca sponsoring and the parties sharing costs.

  Webebs.publicnow.comWebza.investing.comWebmarketscreener.com
• analyst_ratingSep 25

  Piper Sandler analyst Kelsey Goodwin maintained a Hold rating on Summit Therapeutics with a $16.00 price target.

  Webstockanalysis.com
• Key eventanalyst_ratingSep 25

  Citizens JMP reiterated a Market Outperform rating and $40.00 price target on Summit Therapeutics after updated overall survival data from the HARMONi and HARMONi-2 trials were presented at the World Conference on Lung Cancer.

  Webfr.investing.com
• analyst_ratingSep 25

  Citigroup reiterated its Market Outperform (Buy) rating on Summit Therapeutics on September 25, 2026.

  Webmarketbeat.com